Satellite Banner
Technology Networks Header
Thursday, December 18, 2014
 
Register | Sign in
Home Page
  News
Return

SAGE Therapeutics' Epilepticus Drug Receives FDA Fast Track

Published: Wednesday, July 23, 2014
Last Updated: Wednesday, July 23, 2014
Bookmark and Share
Company announces that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Researchers Identify Non-Gluten Proteins as Targets of Immune Response to Wheat in Celiac Disease
The results were reported online in the Journal of Proteome Research.
New Research Unlocks a Mystery of Albinism
A team led by Brown University biologists has discovered the way in which a specific genetic mutation appears to lead to the lack of melanin production underlying a form of albinism.
Predicting Sepsis
Altered white-blood-cell motion in burn patients may warn of infection.
Study Finds Genetic Clue To Menopause-Like Condition In Young Women
NIH-funded research may also contribute to understanding normal menopause.
Stem Cells Faulty In Duchenne Muscular Dystrophy
In a mouse model of Duchenne muscular dystrophy, muscle stem cells express connective-tissue genes associated with fibrosis and muscle weakness, according to a new study.
How Breast Cancer Cells Break Free To Spread In The Body
Analysis of the downstream signaling pathways of a gene called SNAIL could be used to identify potential targets for scientists who are looking for ways to block or slow metastasis.
Multiple Allergic Reactions Traced To Single Protein
Points to new strategy to reduce allergic responses to many medications.
Cutting Out the Cellular Middleman
New technology directly reprograms skin fibroblasts for a new role.
Therapeutic Strategy May Treat a Childhood Neurological Disorder
Researchers have identified a possible therapy to treat neurofibromatosis type 1 or NF1.
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Scroll Up
Scroll Down

SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn